Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Indeed.... instead of injecting foreign biological material into our veins that can prove fatal or hazardous....why doesn't some high up ( bigwig in big pharma R&D / Medical) see the massive light bulb above their heads and realise a bio -friendly and completely natural protein product can easily and safely be delivered to site of viral attack, via like a Moroccan puffa pipe!!!! Snorting is better than injecting, it works better
You could be right given share consolidation and US PI buyers coming through. ITX is going to look a cheap high growth stock in comparison with the higher prevailing US listed valuation multiples for sure = demand on the share
OMG....after reading this thread, can't wait for AGM in person meeting of our cohort of mature beloved shareholders once planning a friendly celebration..to today, now im just imagining the AGM a few injured, few black eyes and a few glasses being thrown around in the local pubs afterwards. What an investment roller coaster this has been so far. Bored now: RM just bring on the end game as we all deserve a break from these slanging matches don't you think?
Perhaps we get more info. soon. If you think about it, with the prospect of our launch of mass fmcg super absorbant products around the corner within 12 months then we are going to have greater plant capacity so this big investment makes perfect sense.
Totally agree, the void of market space we can continue to penetrate is huge. In that context a £ 10m investment really makes sense to accelerate ITX platform forwards. It's an excitingly big number for us to scale up but in the context of this development engine it makes perfect sense. Eg you don't under invest you go for the opportunity that's there
No. I used that word...its one single virus type but maybe connected to others in the portfolio but that's pure guesswork and conjecture. I read into this some grass roots growing only not a sea change but interesting nevertheless.
Head winds reducing for SNG001. just detected strategic u turn of at least one big vax heavy pharma now looking more at therapeutics! for a single major respiratory virus infection franchise area. Say no more...come on buzz. Maybe all the pandemic noise and virus resurgent chaos in the news is getting through.
Shame many of the key influential decision makers in government and global healthcare eco systems are all numb skulls with absolutely zero foresight and will only scramble after SNG001 when the NEXT BAD pandemic is already upon us. E.g. Let's build some sea defences now that half of our new holiday park has just fallen into the sea off Scarborough cliffs due to predictable coastal erosion mentality!!!!
I agrees smartinvestor, the new chair would look pretty silly if he released his first preliminary figures then the auditor strongly disagreed on something. Its covering his risk exposure to double down on accuracy of that RNS.
It's a shamefull our innovation songsheet failed to make the top 10 charts at the start of the covid pandemic. PM and health sectetary skrewed up big time and missed SNG001 completely as all the other Government so called pandemic advisors. It was about affordability for whole population fear . We all know that.
Yes that was a very confident buy or a rich person having a weighted bet. We will find out soon. Haven't seen almost a million shares trade on just a single transaction for a while in ITX. Bodes wellI think for what's ahead
Not ramping, just sharing some recent observations. Noticed that interest in PP seems to be on the up in recent weeks from my independent industry sources. Whether that means vax, monoclonals or other treatment modalities (like our SNG001 hatchling you can all dream about). Nevertheless, it may reflect greater awareness is starting to build in respect of the acute need to be prepared for any and all eventualities (as heightened by triple INFL and RSV
and Covid variant nasties circulating in recent months) and that has to be mildly positive for our investment Outlook. ??
We know ITX is sitting at a 2022 base "conservative" valuation right now so if 2022 was is as good as we all expect then the 2023 base value jumps to 6p to 7p minimum as we derisk and deliver that growth. We've had one value focused buyer buying in already in recent days (the spike) but more will follow as the recurring revenue platform continues to grow. Valuing ITX is fun but there is significant IP R&D value here plus existing recurring blue chip customer cashflow value here too. I'm guessing the IP value is worth c.40% of total value in the SP by tech. driven benchmarks Ive seen a few years ago but often forgotten by folks looking at revenue based valuation multiples. Let's see what next week holds. GLLTHs.
You wouldn't think they would screw up another good senior CV with significant failure risk this time around. So Im concluding a good pivotal phase III trial is close or some collaborative end game is in clear sight. Also any candidates are going to need very high assurance this isn't a no fly asset given the history of the company last year.